OSLO, Norway, January 29, 2015 /PRNewswire/ --
In a retrospective study Hexvix fluorescence-guided bladder resection significantly improved overall survival and recurrence free survival compared to resection performed with standard white light
Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to note that a study on the impact of Hexvix® on survival in bladder cancer patients has been published in the World Journal of Urology.
The study investigated the impact on survival in bladder cancer patients of photodynamic diagnosis (PDD)-guided bladder tumor resection (TUR-BT), including that guided by Hexvix (hexaminolevulinate (HAL)).
The findings from this retrospective study of 224 patients demonstrate for the first time that Hexvix guided TUR-BT in bladder cancer patients, who later progressed to requiring radical cystectomy (RC), significantly increased the three year overall survival (p=0.037) and the median three year recurrence free survival (p=0.002) compared to patients in the comparator group.
Dr. Georgios Gakis of the Department of Urology, Eberhard-Karls University at Tuebingen, Germany and lead author, stated: " Th ese data indicate for the first time that improved patient management with HAL-guided TUR-BT can make a difference in outcomes even for those bladder cancer patients who later progress to advanced disease and require radical cystectomy. "
Kjetil Hestdal, President and CEO of Photocure, said: " Th ese exciting data add to the growing clinical evidence that Hexvix/Cysview makes a positive impact on the diagnosis and management of bladder cancer in multiple patient types. We believe the continuously increasing adoption of H exvix / Cysview guided TUR-BT will bring significant clinical and health economic benefit to urologists, patients and payers fighting the disease . "
The paper was a retrospective analysis of data from 224 consecutive bladder cancer patients undergoing RC. Of these patients, prior to RC, 66 (29.5%) underwent hexaminolevulinate (HAL)-guided bladder tumor resection (TUR-BT), 23 (10%) 5-aminolevulinate (ALA)-guided TUR-BT and 135 (60.2%) white light (WL)-guided TUR-BT.
Help employers find you! Check out all the jobs and post your resume.
In a retrospective study Hexvix fluorescence-guided bladder resection significantly improved overall survival and recurrence free survival compared to resection performed with standard white light
Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to note that a study on the impact of Hexvix® on survival in bladder cancer patients has been published in the World Journal of Urology.
The study investigated the impact on survival in bladder cancer patients of photodynamic diagnosis (PDD)-guided bladder tumor resection (TUR-BT), including that guided by Hexvix (hexaminolevulinate (HAL)).
The findings from this retrospective study of 224 patients demonstrate for the first time that Hexvix guided TUR-BT in bladder cancer patients, who later progressed to requiring radical cystectomy (RC), significantly increased the three year overall survival (p=0.037) and the median three year recurrence free survival (p=0.002) compared to patients in the comparator group.
Dr. Georgios Gakis of the Department of Urology, Eberhard-Karls University at Tuebingen, Germany and lead author, stated: " Th ese data indicate for the first time that improved patient management with HAL-guided TUR-BT can make a difference in outcomes even for those bladder cancer patients who later progress to advanced disease and require radical cystectomy. "
Kjetil Hestdal, President and CEO of Photocure, said: " Th ese exciting data add to the growing clinical evidence that Hexvix/Cysview makes a positive impact on the diagnosis and management of bladder cancer in multiple patient types. We believe the continuously increasing adoption of H exvix / Cysview guided TUR-BT will bring significant clinical and health economic benefit to urologists, patients and payers fighting the disease . "
The paper was a retrospective analysis of data from 224 consecutive bladder cancer patients undergoing RC. Of these patients, prior to RC, 66 (29.5%) underwent hexaminolevulinate (HAL)-guided bladder tumor resection (TUR-BT), 23 (10%) 5-aminolevulinate (ALA)-guided TUR-BT and 135 (60.2%) white light (WL)-guided TUR-BT.
Help employers find you! Check out all the jobs and post your resume.
